Literature DB >> 15542182

Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children.

Karine Lacombe1, Abdoulaye Yam, Kirsten Simondon, Sybil Pinchinat, François Simondon.   

Abstract

Although use of acellular pertussis vaccine was associated with a higher rate of vaccine failure than that of whole-cell vaccine in the Senegal Pertussis Trial conducted in 1990-1994 on 4189 children, risk factors for vaccine failure regarding exposure and susceptibility to pertussis have not been studied so far. Pertussis occurred in 346 vaccinated children. Three factors were found to be associated with vaccine failure, independently of the vaccine type, namely the degree of exposure, birth rank, and time since weaning. In the whole-cell vaccine group, the risk of failure increased with birth rank [RR = 2.95 (1.51-5.75)] and was higher in non stunted children [RR = 1.43 (1.05-1.94)]. In the acellular vaccine group, the risk of failure increased with age at exposure to B. pertussis [RR = 2.24 (1.21-4.12) after 18 months of age] and the degree of exposure [RR = 2.14 (1.17-3.93) when the child shared the hut of an index case]. These results highlight the influence of environmental factors on the success of pertussis vaccination. However, they do not explain the shorter duration of protection provided by the acellular vaccine compared to the whole-cell vaccine which persist after controlling and thus might be related to the nature of the vaccine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542182     DOI: 10.1016/j.vaccine.2004.07.007

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Pertussis in rural populations of Saskatchewan (1995 to 2003): incidence, seasonality, and differences among cases.

Authors:  David Vickers; Raúl C Mainar-Jaime; Punam Pahwa
Journal:  Can J Public Health       Date:  2006 Nov-Dec

Review 2.  What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.

Authors:  Nicolas Burdin; Lori Kestenbaum Handy; Stanley A Plotkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

3.  Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children.

Authors:  David Vickers; Allen G Ross; Raúl C Mainar-Jaime; Cordell Neudorf; Syed Shah
Journal:  CMAJ       Date:  2006-11-07       Impact factor: 8.262

4.  Characteristics of pertussis outbreaks in Catalonia, Spain, 1997 to 2010.

Authors:  Inma Crespo; Sonia Broner; Núria Soldevila; Ana Martínez; Pere Godoy; Maria-Rosa Sala-Farré; Maria Company; Cristina Rius; Angela Domínguez; The Pertussis Working Group Of Catalonia
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

5.  Seroprevalence of pertussis in Senegal: a prospective study.

Authors:  Lobna Gaayeb; Jean Biram Sarr; Mamadou O Ndiath; Jean-Baptiste Hanon; Anne-Sophie Debrie; Modou Seck; Anne-Marie Schacht; Franck Remoué; Emmanuel Hermann; Gilles Riveau
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

Review 6.  Whole-cell pertussis vaccine in early infancy for the prevention of allergy in children.

Authors:  Gladymar Perez Chacon; Jessica Ramsay; Christopher G Brennan-Jones; Marie J Estcourt; Peter Richmond; Patrick Holt; Tom Snelling
Journal:  Cochrane Database Syst Rev       Date:  2021-09-06

7.  Pertussis Vaccination Failure in the New Zealand Pediatric Population: Study Protocol.

Authors:  Hannah Chisholm; Anna Howe; Emma Best; Helen Petousis-Harris
Journal:  Vaccines (Basel)       Date:  2019-07-16

8.  Geographical differences in whooping cough in Catalonia, Spain, from 1990 to 2010.

Authors:  Inma Crespo; Núria Soldevila; Pilar Muñoz; Pere Godoy; Gloria Carmona; Angela Domínguez
Journal:  BMC Public Health       Date:  2014-03-20       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.